Randomised trial of an inhaled β2 agonist, inhaled corticosteroid and their combination in the treatment of asthma

Hancox, R. J.; J. O. Cowan; E. M. Flannery; G. P. Herbison; C. R. McLachlan; C. S. Wong; D. R. Taylor
June 1999
Thorax;Jun1999, p482
Academic Journal
No abstract available.


Related Articles

  • Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. Svedsater, Henrik; Jacques, Loretta; Goldfrad, Caroline; Bleecker, Eugene R. // Primary Care Respiratory Society UK;6/26/2014, p1 

    The article offers the authors' randomised controlled trials on the application of the Ellipta dry powder inhaler (DPI) in patients suffering from asthma. They mention that the handheld inhaler features a cover with mouthpiece and actuated dose as well as utilized in delivering the inhaled...

  • The use of combined inhalers in asthma. Cates, Christopher // Practice Nursing;Oct2008, Vol. 19 Issue 10, p508 

    The article focuses on the use of inhaled therapy for asthma and how to adjust therapy to suit individual needs. It mentions different types of inhaled therapy including inhaled steroids, beta agonists, combination inhalers, and corticosteroids. A table which outlines the recommended step...

  • The risk of asthma mortality with inhaled long acting β-agonists. Wijesinghe, M.; Perrin, K.; Harwood, M.; Weatherall, M.; Beasley, R. // Postgraduate Medical Journal;Sep2008, Vol. 84 Issue 995, p467 

    This article reviews the available evidence as to whether inhaled long acting β-agonists (LABA) increase the risk of asthma mortality and considers the implications for the use of this treatment in the management of asthma. Randomised controlled trials suggest that LABAs pre- scribed as...

  • Beclometasone Dipropionate/Formoterol in an HFA-Propelled Pressurised Metered-Dose Inhaler. Barnes, Peter J. // Drugs;2006, Vol. 66 Issue 11, p1484 

    The article reports on the treatment of asthma. The combination of corticosteroid inhalers and B2-agonist are considered the most effective treatments of asthma and in other chronic obstructive pulmonary diseases. Some of the examples of B2-agonists are fluticasone propionate, salmeterol and...

  • Weighing up risks in the use of LABAs. Upadhyay, Neil // GP: General Practitioner;2/16/2007, p35 

    The article assesses the risks involved in the use of long-acting beta-2 agonists (LABAs). LABAs should be used after a trial of low-dose inhaled corticosteroids and before the dose of inhaled corticosteroids is increased. LABAs are used to treat patients whose asthma is so severe that treatment...

  • Single LABA inhalers potentially unsafe. Cameron, Amanda // New Zealand Doctor;6/14/2006, p12 

    Reports on the claim of respiratory physician Richard Beasley that single asthma inhalers that dispense a long-acting beta agonist (LABA) are potentially unsafe when used in unstable patients without inhaled corticosteroids treatment. Physiological effect of single LABA inhalers; Information on...

  • Best options for asthma treatment?  // PharmacoEconomics & Outcomes News;1/8/2011, Issue 619, p7 

    The article discusses two studies which examined the health care costs associated with the use of inhaled corticosteroid and long-acting Î’-agonist (ICS/LABA) combination products for the treatment of patients with mild asthma.

  • Maintenance treatment for adults with chronic asthma. Cates, Christopher // BMJ: British Medical Journal;5/17/2014, Vol. 348 Issue 7958, p7 

    The author discusses a network of clinical trials that sought to determine which treatment for asthma is most likely to lower the risk of exacerbation in adults. Topics addressed include the superiority of combined long acting beta agonists and inhaled corticosteroids, tailoring treatment to the...

  • Management of asthma in adults. Balter, Meyer S.; Bell, Alan D.; Kaplan, Alan G.; Kim, Harold; McIvor, R. Andrew // CMAJ: Canadian Medical Association Journal;12/8/2009, Vol. 181 Issue 12, p915 

    The article discusses the management of asthma in adults in Canada. It states that asthma remains the common chronic disease of young adults which can be initially treated by using low-dose inhaled corticosteroids. It notes that a combination therapy with long-acting ß2-agonists and a single...

  • LUNG ALERT: Doubling the dose of inhaled corticosteroid for asthma exacerbations does not decrease subsequent use of systematic steroids. Soth, M. // Thorax;Apr2004, Vol. 59 Issue 4, p346 

    This double blinded trial with concealed randomisation compared doubling the dose of inhaled corticosteroid for 14 days with continuing the same dose when asthma symptoms or peak flow worsened in patients monitoring themselves daily at home. All patients were using an inhaled corticosteroid...


Read the Article


Sign out of this library

Other Topics